Search
for
Sort by
Research 781–810 of 1000+
- Recipient site creation for hair transplantation: A prospective half-side comparison study of hole versus slit
- Lineage Commitment of Dermal Fibroblast Progenitors is Mediated by Chromatin De-repression
- Diseases of the Canine Prostate Gland
- Comment on scalp neuropathy in androgenetic alopecia
- Regenerative Medicine Treatments for Androgenetic Alopecia
- Evolution of Hair Transplant Surgery in India: A Plastic Surgeon's Perspective
- Epidemiologic and Molecular Characterization of Zoonotic Dermatophytes from Pet Dogs and Cats in Egypt
- Hair loss in infancy and childhood
- Periorbital rejuvenation
- AUTOLOGOUS PLATELET‐RICH PLASMA: A REVIEW OF SCIENTIFIC ARTICLES ON THE STUDY OF EFFICIENCY IN TREATMENT OF ANDROGENETIC ALOPECIA IN MEN AND WOMEN
- Anti-Alopecic Activity of a Novel Compound from Aloe barbadensis Miller
- Clinical Considerations of Bioequivalence for Topical Dermatologic Drugs
- Laser Hair Removal in the Asian Skin
- Mesotherapy
- Shushing down the epigenetic landscape towards stem cell differentiation
- Hair Restoration Surgery in Asian Women
- Follicular unit extraction
- Removal of Unwanted Facial Hair
- Baldness Surgery: Megasessions with Follicular Units
- Cosmetic aspects of cranial reconstruction
- Chemical Peels: The Common Channel
- Clinical Outcomes of Ritlecitinib in Treatment-Refractory Alopecia Areata: A Single-Center Real-World Study
- A Cost-per-Responder Analysis of Ritlecitinib vs Baricitinib in Severe Alopecia Areata
- Ritlecitinib: Efficacy of a Novel Therapy for Severe Alopecia Areata in Patients Aged 12 Years and Older
- Real-World Ritlecitinib Treatment of Severe Alopecia Areata (AA) in the US: Patient Characteristics and Physician Satisfaction
- Multiomics Analysis of the Response to Ritlecitinib in Alopecia Areata Subtypes and Correlation With Efficacy
- Alopecia areata and ritlecitinib: Unravelling response trajectories
- Efficacy and Safety of Switching from Baricitinib to Ritlecitinib in Severe Alopecia Areata
- Efficacy of Ritlecitinib in Patients with Alopecia Areata by Extent of Hair Loss: Results from the Phase 2b/3 and Phase 3 ALLEGRO Clinical Trials
- Distribution of SALT Scores with Ritlecitinib Treatment up to 24 months from the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia Areata